We are live on
!
Find out more
RHJA
Rice Hall James & Associates Portfolio holdings
AUM
$1.8B
1-Year Est. Return
36.16%
This Fund
S&P 500
This Quarter
Est. Return
+9.21%
1 Year Est. Return
+36.16%
3 Year Est. Return
+116.66%
5 Year Est. Return
+140.56%
10 Year Est. Return
+771.9%
AUM
$2.75B
AUM Growth
+$188M
(+7.3%)
Cap. Flow
+$19.8M
Cap. Flow
% of AUM
0.72%
Top 10 Holdings %
Top 10 Hldgs %
19.69%
Holding
327
New
32
Increased
100
Reduced
149
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
|
+$19.1M |
| 2 |
Apogee Enterprises
APOG
|
+$15.9M |
| 3 |
DNOW Inc
DNOW
|
+$15.1M |
| 4 |
PINC
Premier
PINC
|
+$13.4M |
| 5 |
SUM
Summit Materials, Inc. Class A Common Stock
SUM
|
+$12.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Supernus Pharmaceuticals
SUPN
|
+$25.9M |
| 2 |
STMP
Stamps.com, Inc.
STMP
|
+$17.4M |
| 3 |
Viasat
VSAT
|
+$17M |
| 4 |
CVGW
Calavo Growers
CVGW
|
+$15.3M |
| 5 |
REVG
REV Group
REVG
|
+$15.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.97% |
| 2 | Industrials | 19.87% |
| 3 | Technology | 17.13% |
| 4 | Consumer Discretionary | 9.66% |
| 5 | Communication Services | 7.15% |
Similar funds
GC
BP
CIM
JCM
KPM
BFG
ST
MCC
Rice Hall James & Associates's Q2 2018 Portfolio in Review
As of Q2 2018, Rice Hall James & Associates held 327 positions worth $2.75B, up 7.3% from $2.56B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Rice Hall James & Associates's Q2 2018 filing shows 32 new, 100 increased, 149 reduced and 29 closed positions. Its largest new stake was DIPLOMAT PHARMACY, INC.: 818,939 shares worth $20.9M. The largest sale was Supernus Pharmaceuticals, an estimated $25.9M.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 23% a quarter earlier, followed by Industrials and Technology.
- Rice Hall James & Associates's largest Q2 2018 buy was DIPLOMAT PHARMACY, INC.: 818,939 shares worth $20.9M.
- Rice Hall James & Associates added most to Apogee Enterprises in Q2 2018, an estimated $15.9M increase.
- Rice Hall James & Associates's biggest Q2 2018 reduction was Supernus Pharmaceuticals, cutting an estimated $25.9M.
- Rice Hall James & Associates fully exited Viasat in Q2 2018, selling an estimated $17M.
- Rice Hall James & Associates's ten largest holdings make up 20% of its $2.75B portfolio in Q2 2018.
- Rice Hall James & Associates opened 32 new positions and closed 29 in Q2 2018.
- Rice Hall James & Associates's portfolio value rose 7.3% quarter-over-quarter to $2.75B.
Based on Rice Hall James & Associates's 13F filing for Q2 2018, filed 2 Aug 2018.